Sildenafil Pill Images

In the following patients: age >65 years, hepatic impairment (e.g., cirrhosis), severe renal

2.4 Dosage Adjustments Due to Drug Interactions

In studies with healthy volunteers of single doses up to 800 mg, adverse reactions were similar to those seen at lower doses but incidence rates and severities were increased. Each tablet contains sildenafil citrate USP equivalent to 25 mg, 50 mg and 100 mg of sildenafil. Sildenafil tablets USP, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Sildenafil tablets, USP are formulated as white to off-white, diamond shaped, biconvex, film-coated tablets for oral administration. 12 CLINICAL PHARMACOLOGY 12.1 150mg sildenafil for sale Mechanism of ActionThe physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation.

Dosage for pulmonary arterial hypertension (PAH)

NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood.Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum. When sexual stimulation causes local release of NO, inhibition of PDE5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil at recommended doses has no effect in the absence of sexual stimulation.Binding CharacteristicsStudies in vitro have shown that sildenafil is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, >80-fold for PDE1, >700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). Sildenafil is approximately 4,000-fold more selective for PDE5 compared to PDE3. impairment (e.g., creatinine clearance <30 mL/min), and concomitant use of erythromycin or strong

CYP3A4 inhibitors, plasma levels of sildenafil at 24 hours post dose have been found to be 3 to 8 times higher than those seen in healthy volunteers.

5.2 Prolonged Erection and Priapism

Sildenafil is not indicated for use in females. There are no data with the use of sildenafil in pregnant women to inform any drug-associated risks for adverse developmental outcomes. Animal reproduction studies conducted with sildenafil did not show adverse developmental outcomes when administered during organogenesis in rats and rabbits at oral doses up to 16 and 32 times, respectively, the maximum recommended human dose (MRHD) of 100 mg/day on a mg/m2 basis (see Data). No evidence of teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits which received oral doses up to 200 mg/kg/day during organogenesis. In the rat pre- and postnatal development study, the no observed adverse effect dose was 30 mg/kg/day given for 36 days, about 2 times the MRHD on a mg/m2 basis in a 50 kg subject.

How is sildenafil supplied (dosage forms)?

Limited data indicate that sildenafil and its active metabolite are present in human milk. There is no information on the effects on the breastfed child, or the effects on milk production. No dose adjustment is required for mild (CLcr=50 to 80 mL/min) and moderate (CLcr = 30 to 49 mL/min) renal impairment. A starting dose of 25 mg should be considered in patients with severe renal impairment [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)]. 10 OVERDOSAGE In studies with healthy volunteers of single doses up to 800 mg, adverse reactions were similar to those seen at lower doses but incidence rates and severities were increased.In cases of overdose, standard supportive measures should be adopted as required. Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be

safely co-administered at this time point [see Contraindications (4.1)].Effects of Sildenafil on

Blood Pressure When Co-administered with Alpha-Blockers:Three double-blind, placebo-controlled, randomized, two-way crossover studies

• Sildenafil white was first approved by the FDA in 1998.
• It is marketed under various brand and generic names worldwide.
• The drug belongs to a class called phosphodiesterase inhibitors.
• It is effective for many men with both physical and psychological ED.
• Sildenafil white may also help treat pulmonary arterial hypertension.
• Some users report experiencing visual disturbances after taking it.
• The medication’s effects last approximately 4 to 6 hours.
• It is advisable to avoid alcohol when taking sildenafil white.
• Consumers should check for potential drug allergies before use.
• The pill's color and shape can vary depending on the manufacturer.
• Always consult a healthcare provider for appropriate use and dosing.

were conducted to assess the interaction of sildenafil with doxazosin, an alpha-adrenergic

• Sildenafil white is a common name for the generic version of Viagra.
• It is used to treat erectile dysfunction in men.
• Sildenafil white is known for its rapid onset of action.
• The medication works by enhancing blood flow to the penis.
• It is typically taken about 30 to 60 minutes before sexual activity.
• Sildenafil white is available in various doses, usually 25mg, 50mg, and 100mg.
• The drug should not be used with nitrate medications to avoid dangerous interactions.
• Common side effects include headache, flushing, and nasal congestion.
• It is important to follow dosage instructions provided by a healthcare provider.
• Sildenafil white can cause low blood pressure in some users.
• Store sildenafil white in a cool, dry place, away from direct sunlight.

blocking agent.Study 1: Sildenafil with DoxazosinIn the first study, a single oral

12.1 Mechanism of Action

These doses represent, respectively, about 16 and 32 times the MRHD on a mg/m2 basis in a 50 kg subject. In the rat pre- and postnatal development study, the no observed adverse effect dose was 30 mg/kg/day given for 36 days, about 2 times the MRHD on a mg/m2 basis in a 50 kg subject.8.2 LactationRisk SummarySildenafil is not indicated for use in females.Limited data indicate that sildenafil and its active metabolite are present in human milk. There is no information on the effects on the breastfed child, or the effects on milk production.8.4 Pediatric UseSildenafil is not indicated for use in pediatric patients. Safety and effectiveness have not been established in pediatric patients.8.5 Geriatric UseHealthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil resulting in approximately 84% and 107% higher plasma AUC values of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy young volunteers (18 to 45 years) [see Clinical Pharmacology (12.3)]. Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively [see Clinical Pharmacology (12.3)].Of the total number of subjects in clinical studies of sildenafil, 18% were 65 years and older, while 2% were 75 years and older.

Clinical monitoring

No overall differences in safety or efficacy were observed between older (> 65 years of age) and younger (< 65 years of age) subjects.However, since higher plasma levels may increase the incidence of adverse reactions, a starting dose of 25 mg should be considered in older subjects due to the higher systemic exposure [see Dosage and Administration (2.5)].8.6 Renal ImpairmentNo dose adjustment is required for mild (CLcr=50 to 80 mL/min) and moderate (CLcr = 30 to 49 mL/min) renal impairment. In volunteers with severe renal impairment (Clcr<30 mL/min), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (~2 fold), approximately doubling of Cmax and AUC. A starting dose of 25 mg should be considered in patients with severe renal impairment [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)].8.7 Hepatic ImpairmentIn volunteers with hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (47% for Cmax and 85% for AUC). The pharmacokinetics of sildenafil in patients with severely impaired hepatic function (Child-Pugh Class C) have not sildenafil citrates been studied. A starting dose of 25 mg should be considered in patients with any degree of hepatic impairment [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)]. dose of sildenafil 100 mg or matching placebo was administered in a 2-period crossover design to 4 generally healthy males with benign prostatic hyperplasia (BPH).

5.7 Combination with other PDE5 Inhibitors or Other Erectile Dysfunction Therapies

PDE3 is involved in control of cardiac contractility. Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina which is involved in the phototransduction pathway of the retina. This lower selectivity is thought to be the basis for abnormalities related to color vision [see Clinical Pharmacology (12.2)].In addition to human corpus cavernosum smooth muscle, PDE5 is also found in other tissues including platelets, vascular and visceral smooth muscle, and skeletal muscle, brain, heart, liver, kidney, lung, pancreas, prostate, bladder, testis, and seminal vesicle. The inhibition of PDE5 in some of these tissues by sildenafil may be the basis for the enhanced platelet antiaggregatory activity of NO observed in vitro, an inhibition of platelet thrombus formation in vivo and peripheral arterial-venous dilatation in vivo.12.2 PharmacodynamicsEffects of Sildenafil on Erectile Response: In eight double-blind, placebo-controlled crossover studies of patients with either organic or psychogenic erectile dysfunction, sexual stimulation resulted in improved erections, as assessed by an objective measurement of hardness and duration of erections (RigiScan®), after sildenafil administration compared with placebo. Most studies assessed the efficacy of sildenafil approximately 60 minutes post dose.

Incidence not known

The erectile response, as assessed by RigiScan®, generally increased with increasing sildenafil dose and plasma concentration. The time course of effect was examined in one study, showing an effect for up to 4 hours but the response was diminished compared to 2 hours.Effects of Sildenafil on Blood Pressure: Single oral doses of sildenafil (100 mg) administered to healthy volunteers produced decreases in sitting blood pressure (mean maximum decrease in systolic/diastolic blood pressure of 8.3/5.3 mmHg). The decrease in sitting blood pressure was most notable approximately 1 to 2 hours after dosing, and was not different than placebo at sildenafil tablets lp 100 mg 8 hours. Similar effects on blood pressure were noted with 25 mg, 50 mg and 100 mg of sildenafil, therefore the effects are not related to dose or plasma levels within this dosage range. Larger effects were recorded among patients receiving concomitant nitrates [see Contraindications (4.1)].Effects of Sildenafil on Blood Pressure When Nitroglycerin is Subsequently Administered:Based on the pharmacokinetic profile of a single 100 mg oral dose given to healthy normal volunteers, the plasma levels of sildenafil at 24 hours post dose are approximately 2 ng/mL (compared to peak plasma levels of approximately 440 ng/mL). Following at least 14 consecutive daily doses of doxazosin, sildenafil 100 mg or matching placebo was administered simultaneously with doxazosin. Following a review of the data from these first 4 subjects (details provided below), the sildenafil dose was reduced to 25 mg.

• The term 'sildenafil white' often refers to unbranded, generic pills.
• It may be available online through various pharmacies and vendors.
• Users should verify the legitimacy of sildenafil sources to avoid fake products.
• This medication is not suitable for individuals with certain heart conditions.
• Sildenafil white is sometimes used recreationally for its euphoric effects.
• It may interact with certain antibiotics and antifungals, altering effectiveness.
• Patients should inform their doctor of all medications before use.
• The medication is not an aphrodisiac; it only facilitates erectile response.
• Overuse or misuse of sildenafil white can lead to serious health risks.
• The recommended maximum frequency is once per day unless advised otherwise.
• Consultation with a healthcare professional is essential prior to use.